Zoetis Announced Earlier It Will Sell Its Medicated Feed Additive Portfolio To Phibro Animal Health For $350M

4/28/24 8:09:52 PM ET

$PAHC

$ZTS

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PAHC alert in real time by email

Zoetis Inc. (NYSE:ZTS) and Phibro Animal Health Corporation (NASDAQ:PAHC) today announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis' medicated feed additive (MFA) product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024.

This press release features multimedia. View the full release here:

Get the next $PAHC alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$PAHC
$ZTS

Company	Date	Price Target	Rating	Analyst
Zoetis Inc. $ZTS	1/22/2026	$135.00	Overweight → Neutral	Piper Sandler
Zoetis Inc. $ZTS	12/15/2025	$135.00	Buy → Neutral	BofA Securities
Zoetis Inc. $ZTS	12/9/2025	$136.00	Equal Weight	Barclays
Zoetis Inc. $ZTS	11/21/2025		Sector Weight	KeyBanc Capital Markets
Zoetis Inc. $ZTS	7/17/2025	$155.00	Outperform → Market Perform	Leerink Partners
Phibro Animal Health Corporation $PAHC	7/7/2025	$35.00	Neutral → Overweight	Analyst
Zoetis Inc. $ZTS	6/18/2025	$160.00	Buy → Hold	Stifel
Phibro Animal Health Corporation $PAHC	6/16/2025	$24.00	Underperform → Neutral	BNP Paribas Exane

More analyst ratings

Zoetis Announced Earlier It Will Sell Its Medicated Feed Additive Portfolio To Phibro Animal Health For $350M

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$PAHC
$ZTS

Zoetis Announced Earlier It Will Sell Its Medicated Feed Additive Portfolio To Phibro Animal Health For $350M

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$PAHC
$ZTS

$PAHC
$ZTS
Analyst Ratings

Zoetis downgraded by Piper Sandler with a new price target

Zoetis downgraded by BofA Securities with a new price target

Barclays initiated coverage on Zoetis with a new price target

$PAHC
$ZTS
SEC Filings

SEC Form 144 filed by Zoetis Inc.

SEC Form 10-K filed by Zoetis Inc.

Zoetis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$PAHC
$ZTS
Insider Purchases

Director Corcoran E Thomas bought $110,500 worth of shares (5,000 units at $22.10), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

Director Corcoran E Thomas bought $100,100 worth of shares (5,000 units at $20.02), increasing direct ownership by 25% to 25,000 units (SEC Form 4)

$PAHC
$ZTS
FDA approvals

January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

$PAHC
$ZTS
Press Releases

Zoetis to Participate in the KeyBanc Capital Markets Healthcare Forum

Zoetis to Participate in Upcoming Investor Conferences

Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation

$PAHC
$ZTS
Insider Trading

SEC Form 4 filed by Bendheim Jack

President and CEO Bendheim Jack converted options into 100,000 shares and sold $258,245 worth of shares (5,280 units at $48.91) (SEC Form 4)

Director Norden Gregory gifted 1,213 shares, closing all direct ownership in the company (SEC Form 4)

$PAHC
$ZTS
Leadership Updates

Phibro Animal Health Corporation Announces Leadership Transition

Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

Zoetis Appoints Stephanie Tilenius to its Board of Directors

$PAHC
$ZTS
Financials

Zoetis Reports Fourth Quarter and Full Year 2025 Results

Zoetis Declares Second Quarter 2026 Dividend

Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance

$PAHC
$ZTS
Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Phibro Animal Health Corporation

Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

Zoetis Announced Earlier It Will Sell Its Medicated Feed Additive Portfolio To Phibro Animal Health For $350M

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $PAHC$ZTS

Zoetis Announced Earlier It Will Sell Its Medicated Feed Additive Portfolio To Phibro Animal Health For $350M

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $PAHC$ZTS

$PAHC$ZTS Analyst Ratings

Zoetis downgraded by Piper Sandler with a new price target

Zoetis downgraded by BofA Securities with a new price target

Barclays initiated coverage on Zoetis with a new price target

$PAHC$ZTS SEC Filings

SEC Form 144 filed by Zoetis Inc.

SEC Form 10-K filed by Zoetis Inc.

Zoetis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$PAHC$ZTS Insider Purchases

Director Corcoran E Thomas bought $110,500 worth of shares (5,000 units at $22.10), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

Director Corcoran E Thomas bought $100,100 worth of shares (5,000 units at $20.02), increasing direct ownership by 25% to 25,000 units (SEC Form 4)

$PAHC$ZTS FDA approvals

January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

$PAHC$ZTS Press Releases

Zoetis to Participate in the KeyBanc Capital Markets Healthcare Forum

Zoetis to Participate in Upcoming Investor Conferences

Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation

$PAHC$ZTS Insider Trading

SEC Form 4 filed by Bendheim Jack

President and CEO Bendheim Jack converted options into 100,000 shares and sold $258,245 worth of shares (5,280 units at $48.91) (SEC Form 4)

Director Norden Gregory gifted 1,213 shares, closing all direct ownership in the company (SEC Form 4)

$PAHC$ZTS Leadership Updates

Phibro Animal Health Corporation Announces Leadership Transition

Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

Zoetis Appoints Stephanie Tilenius to its Board of Directors

$PAHC$ZTS Financials

Zoetis Reports Fourth Quarter and Full Year 2025 Results

Zoetis Declares Second Quarter 2026 Dividend

Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance

$PAHC$ZTS Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Phibro Animal Health Corporation

Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

Recent Analyst Ratings for
$PAHC
$ZTS

Recent Analyst Ratings for
$PAHC
$ZTS

$PAHC
$ZTS
Analyst Ratings

$PAHC
$ZTS
SEC Filings

$PAHC
$ZTS
Insider Purchases

$PAHC
$ZTS
FDA approvals

$PAHC
$ZTS
Press Releases

$PAHC
$ZTS
Insider Trading

$PAHC
$ZTS
Leadership Updates

$PAHC
$ZTS
Financials

$PAHC
$ZTS
Large Ownership Changes